Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in the US
2011-09-29 · Novo Nordisk A/S · original novonordisk.com ↗
Novo Nordisk today announced the submission to the US Food and Drug Administration of two new drug applications for the approval of ultra-long-acting insulin Degludec and the insulin combination analogue DegludecPlus, respectively. This new generation of insulins has been developed for the treatment of people with type 1 and type 2 diabetes. Further information: Media: Investors: Katrine Sperling Klaus Bülow Davidsen Tel: (+45) 4442 6718 Tel: (+45) 4442 3176 [email protected] [email protected] Frank Daniel Mersebach Tel: (+45) 4442 0604 [email protected] Lars Borup Jacobsen Tel: (+45) 3075 3479 [email protected] In North America: Ambre Morley Jannick Lindegaard Tel: (+1) 609 216 5240 Tel: (+1) 609 786 4575 [email protected] [email protected] Company Announcement no 61 / 2011
The release as fetched from its publisher. novonordisk.com ↗